C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
1.890
+0.060 (3.28%)
At close: Feb 13, 2026, 4:00 PM EST
1.900
+0.010 (0.53%)
After-hours: Feb 13, 2026, 6:06 PM EST
C4 Therapeutics Revenue
C4 Therapeutics had revenue of $11.23M in the quarter ending September 30, 2025, a decrease of -26.90%. This brings the company's revenue in the last twelve months to $30.11M, down -10.57% year-over-year. In the year 2024, C4 Therapeutics had annual revenue of $35.58M with 71.44% growth.
Revenue (ttm)
$30.11M
Revenue Growth
-10.57%
P/S Ratio
4.47
Revenue / Employee
$273,709
Employees
110
Market Cap
183.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35.58M | 14.83M | 71.44% |
| Dec 31, 2023 | 20.76M | -10.34M | -33.25% |
| Dec 31, 2022 | 31.10M | -14.69M | -32.08% |
| Dec 31, 2021 | 45.79M | 12.59M | 37.93% |
| Dec 31, 2020 | 33.20M | 11.81M | 55.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Voyager Therapeutics | 31.32M |
| Sol-Gel Technologies | 18.97M |
| Prelude Therapeutics | 10.50M |
| Tonix Pharmaceuticals Holding | 10.30M |
| Ovid Therapeutics | 6.61M |
| SAB Biotherapeutics | 114.70K |
CCCC News
- 5 days ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 4 weeks ago - C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways - GlobeNewsWire
- 2 months ago - Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss - Seeking Alpha
- 2 months ago - C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 3 months ago - Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
- 3 months ago - C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering - GlobeNewsWire